Literature DB >> 29154018

Improving patient access to hepatitis C virus treatment.

Milena M McLaughlin, Kevin T Marx, Colleen Terriff.   

Abstract

OBJECTIVES: To discuss the current barriers to hepatitis C virus (HCV) treatment; to provide information and resources to assist health care providers with the prior authorization process; to provide resources for potential access to medications if a patient's third-party payer may not be an option; and to discuss the pharmacist's vital role as a patient advocate and considerations once medications are approved.
SUMMARY: Access to HCV medications is often restricted by third-party payers. Pharmacists are poised to fill an immediate need and assist with providing the necessary clinical evidence to gain access to HCV medications and advocate on the patient's behalf. Once approval for HCV treatment has been obtained, considerations must be given to procurement of therapy, refills, monitoring, and avoid interruptions in therapy.
CONCLUSION: The assistance of a pharmacist should be sought to overcome barriers related to medication access. Once therapy has been obtained, the pharmacist can assist the entire patient care team to ensure timely refills, appropriate monitoring, tolerability of therapy, and continued medication access.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29154018     DOI: 10.1016/j.japh.2017.10.013

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  1 in total

1.  Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.

Authors:  Alain H Litwin; John Jost; Katherine Wagner; Moonseong Heo; Alison Karasz; Judith Feinberg; Arthur Y Kim; Paula J Lum; Shruti H Mehta; Lynn E Taylor; Judith I Tsui; Irene Pericot-Valverde; Kimberly Page
Journal:  Contemp Clin Trials       Date:  2019-10-24       Impact factor: 2.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.